{"transactions":[{"id":767680,"issuer":{"id":6248,"kind":"organization","name":"Neuronetics, Inc."},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Former EVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2026-05-21T20:05:15.000Z","date":"2026-03-19","kind":"sale","planned":false,"acquired":false,"shares":8569,"price":1.34,"value":11482.46,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Form 4 filed on March 24, 2026 inadvertently reported the disposition of 16,431 shares of common stock in connection with non-discretionary sales to satisfy the Reporting Person's tax withholding obligation upon vesting of a portion of a performance restricted stock unit award. However, the correct amount is 8,569 shares of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $1.48 to $1.20. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":836643,"source":{"system":"sec-edgar","filing":"0001856059-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1227636/000185605926000002/ownership.xml","form_type":"4/A","original_submission_date":"2026-03-24"}},{"id":829107,"issuer":{"id":6248,"kind":"organization","name":"Neuronetics, Inc."},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2026-03-24T21:52:12.000Z","date":"2026-03-19","kind":"sale","planned":false,"acquired":false,"shares":16431,"price":1.34,"value":22017.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were non-discretionary sales to satisfy the Reporting Person's tax withholding obligation upon vesting of a portion of a performance restricted stock unit award."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $1.48 to $1.20. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":828781,"source":{"system":"sec-edgar","filing":"0001193125-26-122298","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1227636/000119312526122298/ownership.xml","form_type":"4"}},{"id":834757,"issuer":{"id":6248,"kind":"organization","name":"Neuronetics, Inc."},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2026-03-18T20:33:52.000Z","date":"2026-03-17","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award that vests in three equal annual installments beginning on March 17, 2027, in each case subject to continuous service of the Reporting Person through such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":845212,"source":{"system":"sec-edgar","filing":"0001193125-26-114111","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1227636/000119312526114111/ownership.xml","form_type":"4"}},{"id":881717,"issuer":{"id":6248,"kind":"organization","name":"Neuronetics, Inc."},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2026-02-25T21:30:17.000Z","date":"2026-02-23","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award that vests in three equal annual installments beginning on February 23, 2027, in each case subject to continuous service of the Reporting Person through such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":820212,"source":{"system":"sec-edgar","filing":"0001193125-26-071774","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1227636/000119312526071774/ownership.xml","form_type":"4"}},{"id":956408,"issuer":{"id":6248,"kind":"organization","name":"Neuronetics, Inc."},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2025-12-31T22:05:03.000Z","date":"2025-12-30","kind":"grant","planned":false,"acquired":true,"shares":170212,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award that vests on the earlier of (i) June 30, 2027 and (ii) the termination of Mr. Pfanstiel's employment from the Issuer without cause."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":570212,"source":{"system":"sec-edgar","filing":"0001193125-25-338392","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1227636/000119312525338392/ownership.xml","form_type":"4"}},{"id":1087287,"issuer":{"id":6248,"kind":"organization","name":"Neuronetics, Inc."},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2025-07-15T21:00:04.000Z","date":"2025-07-15","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents a RSU award that vests in three equal annual installments beginning on July 15, 2027, in each case subject to continuous service of the Reporting Person through such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":400000,"source":{"system":"sec-edgar","filing":"0000950170-25-095914","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1227636/000095017025095914/ownership.xml","form_type":"4"}},{"id":1087286,"issuer":{"id":6248,"kind":"organization","name":"Neuronetics, Inc."},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2025-07-15T21:00:04.000Z","date":"2025-07-15","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award that vests in three equal annual installments beginning on July 15, 2026, in each case subject to continuous service of the Reporting Person through such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":200000,"source":{"system":"sec-edgar","filing":"0000950170-25-095914","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1227636/000095017025095914/ownership.xml","form_type":"4"}},{"id":1273637,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO AND COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-11T09:13:48.000Z","date":"2025-02-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":220000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":13.99,"expiration_date":"2031-04-12","underlying":"Common Stock","underlying_shares":220000},"source":{"system":"sec-edgar","filing":"0001104659-25-011241","document":"tm255946-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465925011241/tm255946-4_4seq1.xml","form_type":"4"}},{"id":1273636,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO AND COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-11T09:13:48.000Z","date":"2025-02-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":74475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":10.4,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":74475},"source":{"system":"sec-edgar","filing":"0001104659-25-011241","document":"tm255946-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465925011241/tm255946-4_4seq1.xml","form_type":"4"}},{"id":1273635,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO AND COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-11T09:13:48.000Z","date":"2025-02-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":126585,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":5.94,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":126585},"source":{"system":"sec-edgar","filing":"0001104659-25-011241","document":"tm255946-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465925011241/tm255946-4_4seq1.xml","form_type":"4"}},{"id":1273634,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO AND COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-11T09:13:48.000Z","date":"2025-02-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":114600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":9.74,"expiration_date":"2034-01-18","underlying":"Common Stock","underlying_shares":114600},"source":{"system":"sec-edgar","filing":"0001104659-25-011241","document":"tm255946-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465925011241/tm255946-4_4seq1.xml","form_type":"4"}},{"id":1273633,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO AND COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-11T09:13:48.000Z","date":"2025-02-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":57300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":1.4,"expiration_date":"2034-06-18","underlying":"Common Stock","underlying_shares":57300},"source":{"system":"sec-edgar","filing":"0001104659-25-011241","document":"tm255946-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465925011241/tm255946-4_4seq1.xml","form_type":"4"}},{"id":1273632,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO AND COO"}}],"security":"Common Stock","published_at":"2025-02-11T09:13:48.000Z","date":"2025-02-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":62470,"price":0.55,"value":34358.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden (\"Parent\"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the \"Offer Price\") in cash."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents 62,470 shares underlying Restricted Stock Units (the \"RSUs\"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the \"Effective Time\"), each outstanding RSU was terminated in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden (\"Parent\"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the \"Offer Price\") in cash."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-011241","document":"tm255946-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465925011241/tm255946-4_4seq1.xml","form_type":"4"}},{"id":1273631,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO AND COO"}}],"security":"Common Stock","published_at":"2025-02-11T09:13:48.000Z","date":"2025-02-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17303,"price":0.55,"value":9516.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden (\"Parent\"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the \"Offer Price\") in cash."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden (\"Parent\"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the \"Offer Price\") in cash."}],"balance_after":62470,"source":{"system":"sec-edgar","filing":"0001104659-25-011241","document":"tm255946-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465925011241/tm255946-4_4seq1.xml","form_type":"4"}},{"id":1438658,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO AND COO"}}],"security":"Common Stock","published_at":"2024-08-07T16:05:17.000Z","date":"2024-08-05","kind":"sale","planned":false,"acquired":false,"shares":4657,"price":1.13,"value":5262.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the \"Company\") sold by the reporting person pursuant to\na Rule 10b5-1 Plan adopted on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $1.11 to $1.16, inclusive. The\nreporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4."}],"balance_after":79773,"source":{"system":"sec-edgar","filing":"0001415889-24-020898","document":"form4-08072024_040810.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000141588924020898/form4-08072024_040810.xml","form_type":"4"}},{"id":1472962,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO AND COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-20T16:21:02.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":57300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable in full on July 15, 2025, subject to the reporting person's continued service with the Issuer."}],"balance_after":57300,"derivative":{"exercise_price":1.4,"expiration_date":"2034-06-18","underlying":"Common Stock","underlying_shares":57300},"source":{"system":"sec-edgar","filing":"0001415889-24-017629","document":"form4-06202024_080659.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000141588924017629/form4-06202024_080659.xml","form_type":"4"}},{"id":1472961,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO AND COO"}}],"security":"Common Stock","published_at":"2024-06-20T16:21:02.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":12733,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (RSUs). The RSUs vest in full on July 15, 2025, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer."}],"balance_after":84430,"source":{"system":"sec-edgar","filing":"0001415889-24-017629","document":"form4-06202024_080659.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000141588924017629/form4-06202024_080659.xml","form_type":"4"}},{"id":1628562,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO AND COO"}}],"security":"Common Stock","published_at":"2024-02-21T16:05:40.000Z","date":"2024-02-16","kind":"sale","planned":false,"acquired":false,"shares":3092,"price":9.97,"value":30827.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the \"Company\") sold by the reporting person pursuant to\na Rule 10b5-1 Plan adopted on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $9.96 to $9.98, inclusive. The\nreporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4."}],"balance_after":71697,"source":{"system":"sec-edgar","filing":"0001415889-24-004576","document":"form4-02212024_040204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000141588924004576/form4-02212024_040204.xml","form_type":"4"}},{"id":1675074,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO AND COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-19T16:19:34.000Z","date":"2024-01-18","kind":"grant","planned":false,"acquired":true,"shares":114600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable in 36 equal monthly installments beginning on February 18, 2024, subject to the reporting person's continued service with the Issuer."}],"balance_after":114600,"derivative":{"exercise_price":9.74,"expiration_date":"2034-01-18","underlying":"Common Stock","underlying_shares":114600},"source":{"system":"sec-edgar","filing":"0001415889-24-001591","document":"form4-01192024_090127.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000141588924001591/form4-01192024_090127.xml","form_type":"4"}},{"id":1675073,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO AND COO"}}],"security":"Common Stock","published_at":"2024-01-19T16:19:34.000Z","date":"2024-01-18","kind":"grant","planned":false,"acquired":true,"shares":25465,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (RSUs). The RSUs vest in three equal installments, with the first installment vesting on February 15, 2025, the second installment vesting on February 15, 2026, and the third installment vesting on February 15, 2027, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer."}],"balance_after":74789,"source":{"system":"sec-edgar","filing":"0001415889-24-001591","document":"form4-01192024_090127.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000141588924001591/form4-01192024_090127.xml","form_type":"4"}},{"id":1812822,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO AND COO"}}],"security":"Common Stock","published_at":"2023-08-08T21:05:14.000Z","date":"2023-08-08","kind":"sale","planned":true,"acquired":false,"shares":14,"price":8.93,"value":125.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the \"Company\") sold by the reporting person pursuant to\na Rule 10b5-1 Plan adopted on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.58 to $8.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4."}],"balance_after":49324,"source":{"system":"sec-edgar","filing":"0001415889-23-011950","document":"form4-08082023_090805.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000141588923011950/form4-08082023_090805.xml","form_type":"4"}},{"id":1812821,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO AND COO"}}],"security":"Common Stock","published_at":"2023-08-08T21:05:14.000Z","date":"2023-08-07","kind":"sale","planned":true,"acquired":false,"shares":2790,"price":9.54,"value":26616.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the \"Company\") sold by the reporting person pursuant to\na Rule 10b5-1 Plan adopted on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $9.38 to $9.83, inclusive. The\nreporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4."}],"balance_after":49338,"source":{"system":"sec-edgar","filing":"0001415889-23-011950","document":"form4-08082023_090805.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000141588923011950/form4-08082023_090805.xml","form_type":"4"}},{"id":2042037,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-30T16:33:07.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":126585,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable in 36 equal monthly installments beginning on February 26, 2023, subject to the reporting person's continued service with the Issuer."}],"balance_after":126585,"derivative":{"exercise_price":5.94,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":126585},"source":{"system":"sec-edgar","filing":"0001415889-23-001581","document":"form4-01302023_090151.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000141588923001581/form4-01302023_090151.xml","form_type":"4"}},{"id":2042036,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2023-01-30T16:33:07.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":28130,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (RSUs). The RSUs vest in three equal installments, with the first installment vesting on February 15, 2024, the second installment vesting on February 15, 2025, and the third installment vesting on February 15, 2026, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer."}],"balance_after":52128,"source":{"system":"sec-edgar","filing":"0001415889-23-001581","document":"form4-01302023_090151.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000141588923001581/form4-01302023_090151.xml","form_type":"4"}},{"id":2255018,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-05-26T16:01:06.000Z","date":"2022-05-24","kind":"grant","acquired":true,"shares":7448,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (RSUs). The RSUs vest in two equal installments, with the first installment vesting on August 4, 2023, and the second installment vesting on August 4, 2024, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer."}],"balance_after":23998,"source":{"system":"sec-edgar","filing":"0001104659-22-065237","document":"tm2216988-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465922065237/tm2216988-2_4seq1.xml","form_type":"4"}},{"id":2409979,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-07T16:13:59.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":74475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable in 36 equal monthly installments beginning on March 4, 2022."}],"balance_after":74475,"derivative":{"exercise_price":10.4,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":74475},"source":{"system":"sec-edgar","filing":"0001104659-22-012794","document":"tm225605-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465922012794/tm225605-11_4seq1.xml","form_type":"4"}},{"id":2409978,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-07T16:13:59.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":16550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (RSUs). The RSUs vest in three equal installments, with the first installment vesting on August 4, 2023, the second installment vesting on August 4, 2024, and the third installment vesting on August 4, 2025, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer."}],"balance_after":16550,"source":{"system":"sec-edgar","filing":"0001104659-22-012794","document":"tm225605-11_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465922012794/tm225605-11_4seq1.xml","form_type":"4"}},{"id":2750280,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":45172,"kind":"person","name":"Pfanstiel Steven","position":1,"cik":"0001856059","reported_name":"Pfanstiel Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Stock option (right to buy)","published_at":"2021-04-13T21:59:19.000Z","date":"2021-04-12","kind":"grant","acquired":true,"shares":220000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options to purchase shares of common stock vest 25% on 4/12/22, and the remainder in 36 equal monthly installments, commencing on 4/30/22."}],"balance_after":220000,"derivative":{"exercise_price":13.99,"expiration_date":"2031-04-12","underlying":"Common Stock","underlying_shares":220000},"source":{"system":"sec-edgar","filing":"0001104659-21-049910","document":"tm2112857-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465921049910/tm2112857-2_4seq1.xml","form_type":"4"}}]}